Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2017 · 10-Q
Revenue$149.40M$149.40M+4.5% vs Q3 2016 Net Income$33.55M$33.55M+57.2% vs Q3 2016 EPS Diluted$0.68$0.68+51.1% vs Q3 2016 Gross Profit$47,800,000+34.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$34,941,000+29.0% Free Cash Flowderived$22,165,000+119.9% Margins · derivedGross margin32.0%+7.2 pt vs Q3 2016
Operating margin32.0%+7.1 pt vs Q3 2016
Net margin22.5%+7.5 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 3, 2017 · 34 d after period end